Determination of ELISA reactive mumps IgG antibodies in MMR vaccine recipients in comparison with MMR vaccine naïve children: a cross sectional study
Keywords:Antibody, Measles, Mumps, Vaccination
Background: Mumps is a vaccine preventable infectious disease characterized by parotitis. In India mumps vaccines are not currently used under NIP. Waning of vaccine-induced immunity is considered to play a central role in the reemergence of mumps. The comprehensive data on the seroepidemiology of measles, mumps, and rubella (MMR) as well as studies which compare the antibody titer among mumps vaccine naïve with mumps vaccinated children are lacking. The aim of our study is to estimate and compare Mumps specific antibody titer in children with and without MMR vaccine. Current study is a cross sectional observational study.
Methods: In 2019/2020, blood samples were collected from 100 healthy children attending immunization clinic in government medical college Kota and associated J. K. Lon maternal and child care hospital Kota. The samples were investigated for MMR IgG antibodies using ELISA.
Results: Out of total 100 children included in the study 32.27% vaccinated and 4.83% Non-vaccinated were positive for Mumps IgG antibody in the age group of 6m to 6 year. While in the age group of 6year to 12 year there was 31.57% and 26.57% positivity respectively. The seroprevalence of measles, mumps and rubella antibodies among 50 MMR vaccinated children was 94%, 64%, and 96% respectively. A high measles and rubella seroprevalence was observed among all children age groups, suggesting an effective control program, while the mumps seroprevalence decreased significantly with age.
Conclusions: The maximum vaccine effectiveness against mumps for 2 doses of MMR vaccine is≈96% therefore the herd immunity threshold to block mumps virus transmission is ≥86%. As per our study only 64% of the vaccinated children were found to have IgG Mumps Ab. In view of morbidity following mumps infection there is a need to incorporate mumps vaccine along with measles and rubella vaccine in the NIP instead of MR.
Plotkin SA, Rubin SA. Mumps vaccines. In: Plotkin SA, Orenstein WA, ed. Vaccines. 7th ed. Elsevier: Philadelpia; 2018.
Hatchette TF, Mahony JB, Chong S, LeBlanc JJ. Difficulty with mumps diagnosis: What is the contribution of mumps mimickers?. J ClinVirol. 2009;46:381-3.
World health organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;7:51-60.
Galazka A, Robertson S, Kraigher A. Mumps and mumps vaccine: Global review. Bull WHO. 1999; 77:3-14.
Atrasheuskaya AV, Kulak MV, Rubin S, Ignatyev GM. Mumps vaccine investigation in Novosibirsk, Russia, 2002-2004. Clin Microbiol Infect. 2007;13: 670-6.
Centers for disease control and prevention. Update: Mumps Outbreak. MMWR Morb Mortal Wkly Rep. 2010;59:125-9.
Kutty PK, McLean HQ, Lawler J, Schulte C, Hudson JM, Blog D, et al. Risk factors for transmission of mumps in a highly vaccinated population in Orange County, NY, 2009-2010. Pediatr Infect Dis J. 2014; 33:121-5.
Global and regional immunization profile; South-East Asia Region. Available at: http:/ /www. who.int /immunization/ monitoring _surveillance/data/gs_ seaprofile.pdf. Accessed on 3 January 2015.
Vashishtha VM, Yadav S, Dabas A, Bansal CP, Agarwal RC, Yewale VN, et al. IAP position paper on burden of mumps in india and vaccination strategies. Indian Pediatr. 2015;52:505-14.
Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999;77(1):3-14.
Carlton R. The association between the measles, mumps, and rubella vaccine and the development of autism: a meta-analysis. Available at: https:// scholarcommons. usf. edu/etd/163. Accessed on 20 May 2021.
Giammanco G1, Li Volti S, Salemi I, GiammancoBilancia G, Mauro L. Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine. Eur J Epidemiol. 1993;9:199-202.
Measles and mumps cases. Available at: https:// timesofindia. indiatimes. com/ life-style/ health-fitness/ health-news/. Accessed on 20 May 2021.
Robertson SE, Cutts FT, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Bull World Health Organ. 1997;75:69-80.
Echevarria JE, Castellanos A, Sanz JC, Perez C, Palacios G, Martinez de, et al. Circulation of mumps virus genotypes in Spain from 1996 to 2007. J Clin Microbiol. 2010;48:1245-54.
Vashishtha VM, Yewale VN, Bansal CP, Mehta PJ. Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (ACVIP). IAP perspectives on measles and rubella elimination strategies. Indian Pediatr. 2014;51:719-22.
Measles, mumps, and rubella (MMR) vaccination: what everyone should know. Available at: https:// www. cdc. gov/ vaccines/ vpd/ mmr/ public/ index. html. Accessed on 20 May 2021.
Immunization Guide. Available at: http:// www. iapindia. org/ files/ IAP% 20 Immunization% 20 Guide% 20 Book_2009_2010. Accessed on 20 May 2021.
O’Shea S, Woodward S, Best JM. Rubella vaccination: persistence of antibodies for 10 to 21 years. Lancet. 1988;2:909.
O’Shea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody response after challenge involunteers with low level of antibody to rubella virus. J Infect Dis. 1983;148:639-47.
NTAGI Minutes and Recommendations Agenda. Available at: https://main.mohfw.gov.in/sites/ default/files/MoM%20NTAGI%202020.pdf. Accessed on 20 May 2021.
Immunization coverage. Available at: http:// www. who. int/mediacenter/factsheets/fs378/en/#. Accessed on 3 April 2018.
Vashishtha VM, Yewale V, Bansal CP, Mehta PJ. IAP perspectives on measles and rubella elimination strategies. Indian Pediatrc. 2014;51:719-21.
Hukic M, Hajdarpasic A, Ravlija J, Ler Z, Baljic R, Dedeic LA, et al. Mumps outbreak in the Federation of Bosnia and Herzegovina with large cohorts of susceptibles and genetically diverse strains of genotype G, Bosnia and Herzegovina, December 2010 to September 2012. Euro Surveill. 2014;19(33): 1-8.
Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistance of Measles , Mumps and Rubella antibodies in an MMR- Vaccinated Cohort: A 20 year Follo-up. J Infect Dis. 2008;197(7):950-6.
Wang Z, Yan R, He H, Li Q, Chen G. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination. PLoS ONE. 2008;9(2): e89361.
Raut CG, Sinha DP, Jayaprakash H, Hanumiah H, Manjunatha MJ. Mumps disease outbreak in Davangere district of Karnataka, India. Indian J Med Microbiol. 2015;33:378-82.
Measles and Rubella initiative: Annual report.2013. Available at: http:// www. who.int/ immunization/ diseases/ measles/mri_ annualreport_ 2013. pdf. Accessed on 3 April 2018.
Adam O. Seroprevalence of measles, mumps, and rubella and genetic characterization of mumps virus in Khartoum, Sudan. Int J Infect Dis. 2020;91:87-93.
WHO position paper. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;7:51-60.
Poethko-Muller C, Mankertz A. Seroprevalence of measles-, mumps- and rubella-specific igg antibodies in german children and adolescents and predictors for seronegativity. PLoS ONE. 2012;7(8):1-12.
Balasubramanian S, Shah A, Chatterjee P, Shivananda S, Guduru V, Soans S, et al. Recommended immunization schedule (2018-19) and update on immunization for children aged 0 through 18 years. Indian Pediatr. 2018;55:1066-74.